rs9316695: Understanding Genetic Links to Trastuzumab Cardiotoxicity
The genetic variant rs9316695 is an intergenic single nucleotide polymorphism that has been investigated for its potential role in trastuzumab-induced cardiotoxicity. Research into this variant aims to better understand why some patients experience heart-related side effects during HER2-positive breast cancer therapy.
What each genotype means
Baseline risk profile
This genotype represents the most common genetic state at this location in many populations. Research has identified this variant as a candidate marker for trastuzumab-induced cardiotoxicity, but current evidence is limited and primarily observed in specific ancestry groups. Please discuss your treatment plan and any concerns regarding cardiac monitoring with your clinician.
This is the most frequent genotype observed across most global populations.
Potential risk association
Carrying one copy of the G allele has been investigated as a potential factor in trastuzumab-induced cardiotoxicity risk. Because the evidence is currently based on limited studies and may be ancestry-specific, this result should not be used to predict individual clinical outcomes. Always consult with your oncologist or pharmacist regarding your specific medication regimen and cardiac health.
This genotype is found at varying frequencies depending on ancestral background, appearing more frequently in some populations than others.
Potential risk association
Carrying two copies of the G allele has been studied as a potential marker for increased susceptibility to trastuzumab-induced cardiotoxicity. The clinical significance of this finding remains under investigation and is not considered a definitive diagnostic tool. Please discuss this information with your healthcare provider to determine if additional cardiac monitoring is appropriate for your care.
This genotype is relatively rare in many populations, with frequency estimates varying significantly by geographic and ancestral origin.
What is rs9316695?
The variant rs9316695 is a single nucleotide polymorphism (SNP) located in an intergenic region of the human genome. In genetics, an intergenic region refers to the stretches of DNA that lie between genes. While these areas do not code for proteins directly, they often contain regulatory elements that can influence how nearby genes are expressed or controlled. Because rs9316695 is not located within a specific gene, its biological function is not as straightforward as variants that alter protein structure. Instead, researchers study such variants to see if they act as markers for broader genetic patterns or regulatory changes that might influence a patient's physiological response to external stressors, such as pharmaceutical treatments. Identifying these markers is a key part of pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs.
Research and Clinical Associations
The primary interest in rs9316695 stems from its identification in genome-wide association studies (GWAS) as a candidate for trastuzumab-induced cardiotoxicity. Trastuzumab is a targeted therapy used for HER2-positive breast cancer, but it is known to carry a risk of cardiac dysfunction, such as a decline in left ventricular ejection fraction. While clinical risk factors like age, hypertension, and prior anthracycline exposure are well-established, researchers are looking for genetic clues to explain why some individuals are more susceptible to these cardiac events than others. The evidence linking rs9316695 to this risk is currently considered moderate. It is important to note that while statistical associations have been observed, these findings are often preliminary. Further large-scale validation studies are required to determine if this variant can reliably predict clinical outcomes or if it is simply a statistical signal that requires more context.
Understanding Your Results
If you have received information about your rs9316695 genotype, it is essential to interpret it within the context of your overall health. This variant is not a diagnostic tool, and having a specific genotype does not guarantee that you will or will not experience side effects from any medication. Genetic associations are complex and often involve multiple genes, environmental factors, and lifestyle choices. You cannot use this information to make independent decisions about your cancer treatment or cardiac care. If you are concerned about the potential side effects of trastuzumab or any other medication, you must discuss these findings with your oncologist or a qualified pharmacist. They can provide personalized guidance based on your full medical history, current cardiac health, and established clinical guidelines, ensuring that your treatment plan is safe and appropriate for your specific needs.
How common is this variant?
The frequency of the rs9316695 alleles is variable across different global populations, and specific prevalence data depends on the ancestral background of the group being studied.
Frequently asked questions
Is rs9316695 a diagnostic test for heart failure?
No, rs9316695 is not a diagnostic test. It is a genetic variant identified in research studies as a potential marker for risk, but it cannot predict whether an individual will develop heart issues.
Should I change my cancer treatment based on this SNP?
You should never change your treatment plan based on genetic information without consulting your doctor. Decisions regarding cancer therapy must be made by your clinical team based on comprehensive medical evidence.
What does 'intergenic' mean for my health?
Intergenic means the variant is located in the DNA between genes. While it may influence gene regulation, it does not directly change the structure of a protein, and its clinical impact is often less direct than other types of mutations.
Where can I find more information on trastuzumab side effects?
You can find reliable information on trastuzumab and its side effects through resources like MedlinePlus Genetics or by speaking directly with your oncology team. They can provide the most accurate information tailored to your specific treatment regimen.
Sources & further reading
Educational information only, last refreshed 10/2/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs9316695?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants
This variant has been investigated for potential associations with trastuzumab-induced cardiotoxicity in Japanese and Singaporean cohorts.
This SNP is part of a set of variants studied for their potential role in trastuzumab-induced cardiotoxicity in Asian populations.
This variant is associated with G6PD deficiency, which can lead to hemolytic anemia upon exposure to certain medications or fava beans.
This variant is a well-established marker in the VKORC1 gene often used in studies regarding warfarin sensitivity and dosing.
This 'Duffy-null' variant is associated with benign ethnic neutropenia and an increased risk of clozapine-induced neutropenia, while providing protection against Plasmodium vivax malaria.
This variant influences the rate of caffeine metabolism and sensitivity to caffeine intake.